SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) -- AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) today announced that Dustin Haines, Chief Executive Officer, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on 11th December. Presentation DetailsEvent: Life Sciences Virtual Investor ForumDate: Thursday, 11th December Time: 11:30 AM ETWebcast: REGISTER HERE Recent Company Highlights FDA-approved solution EchoSolv AS continued to bui ...

Core Insights - Echo IQ has announced significant findings from two studies presented at the AHA Scientific Sessions 2025, highlighting gaps in the current standard-of-care for diagnosing and monitoring severe aortic stenosis (AS) and the potential of EchoSolv AS to improve patient outcomes [1][2]. Company Overview - Echo IQ is an AI and medical technology company focused on enhancing decision-making in cardiology through advanced analytics and AI [14]. - The company aims to transform severe AS care, particularly addressing the shortcomings of the "watchful waiting" strategy for moderate-to-severe AS cases [2][12]. Study Findings - A study involving over 1.2 million patients revealed that the traditional "watchful waiting" approach is inadequate, leading to significant health risks [2][12]. - EchoSolv AS demonstrated superior accuracy in identifying severe AS phenotypes compared to cardiologists, especially in women and low-gradient cases [6][11]. - The male-to-female diagnosis ratio improved from 2.2:1 to 1.1:1 with EchoSolv's implementation, indicating enhanced gender equity in diagnosis [6]. Clinical Implications - The studies underscore the urgent need for improved monitoring and diagnosis of severe AS, as only 36% of women and 45% of men with moderate-to-severe AS received timely intervention [12]. - EchoSolv AS is positioned to facilitate more precise identification of high-risk AS patients, supporting timely clinical decisions regarding interventions [11]. Research Methodology - The studies were conducted by researchers from the University of Notre Dame Australia, utilizing data from the National Echo Database of Australia (NEDA) [9][10]. - The first study compared traditional cardiologist reporting with EchoSolv, analyzing 30,878 echocardiograms [3][5]. - The second study analyzed echocardiography data from 1.18 million subjects, linking health service delivery to patient outcomes [9].